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ABSTRACT
Podocyte injury and resulting albuminuria are hallmarks of diabetic nephropathy, but targeted therapies to
halt or prevent these complications are currently not available. Here, we show that the immune-related
molecule B7-1/CD80 is a critical mediator of podocyte injury in type 2 diabetic nephropathy.We report the
induction of podocyte B7-1 in kidney biopsy specimens from patients with type 2 diabetes. Genetic and
epidemiologic studies revealed the association of two single nucleotide polymorphisms at the B7-1 gene
with diabetic nephropathy. Furthermore, increased levels of the soluble isoform of the B7-1 ligand CD28
correlatedwith the progression to ESRD in individuals with type 2 diabetes. In vitro, high glucose conditions
prompted the phosphatidylinositol 3 kinase–dependent upregulation of B7-1 in podocytes, and the ectopic
expression of B7-1 in podocytes increased apoptosis and induced disruption of the cytoskeleton that were
reversedby theB7-1 inhibitorCTLA4-Ig. Podocyte expressionof B7-1was also induced in vivo in twomurine
models of diabetic nephropathy, and treatment with CTLA4-Ig prevented increased urinary albumin excre-
tion and improved kidney pathology in these animals. Taken together, these results identify B7-1 inhibition
as a potential therapeutic strategy for the prevention or treatment of diabetic nephropathy.
J Am Soc Nephrol 25: 1415–1429, 2014. doi: 10.1681/ASN.2013050518
Type 2 diabetes (T2D) is rapidly becoming the leading
causeof ESRD.1,2Despitemuchprogress and anoverall
improvement in the treatment of diabetic nephropathy
(DN), the development of ESRD remains an epidemic
problem.3 Podocyte foot processes, separated by nar-
row spaces, constitute the ﬁnal barrier to urinary
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protein loss by creating the porous membrane slit diaphragm, the
integrity of which is essential for retaining proteins during ﬁltra-
tion.4,5 A primary hallmark of DN is the progressive damage and
death of glomerular podocytes,1,6–9 resulting in the leaking of pro-
teins into the urine.4
B7-1 isan immune-relatedproteinfoundonantigen-presenting
cells that interactswithCD28andCTLA4onTcells, thusproviding
positive or negative costimulatory signals necessary for T-cell
activation and survival.10 Inductionof podocyte B7-1 is associated
with development of proteinuria in human and murine lupus
nephritis, in a3 integrin knockout mice, in nephrin knockout
mice, and inmicewith LPS-induced proteinuria.5 The latter study
also reported that podocytes exposed to LPS upregulate B7-1 in
vitro and in vivo, thus leading to podocyte abnormalities and pro-
teinuria.5 Of note, B7-1 knockout (B7-12/2) mice are protected
from LPS-induced albuminuria, suggesting a causal link between
podocyte B7-1 expression and proteinuria.5
Abatacept (CTLA4-Ig) is an inhibitor of B7-1 that is currently
used to treat autoimmune diseases.11 Here we show that high
glucose induces podocyte B7-1 expression, thereby contributing
to podocyte morphologic alterations and ultimately to DN, and
that B7-1 blockade with CTLA4-Ig can protect podocytes from
high glucose–induced injuries. These results suggest that the
CD28/B7-1 pathway is relevant to the pathogenesis of T2D
DN in humans, and CTLA4-Ig treatment may therefore offer a
therapeutic strategy to combat DN. This notion is further sup-
ported byour recentﬁndings showing that Abatacept is a therapy
for proteinuria in patients with podocyte B7-1–positive FSGS.12
RESULTS
B7-1 Is Upregulated in Kidney Biopsies Obtained
from a Subset of Patients with T2D and DN
To address whether B7-1 plays a role in human DN, we analyzed
the expression of B7-1 in kidney biopsies of 30 individuals with
T2D and DN at different stages of severity and from 30 controls
(with surgically removed cancer-affected kidneys) (Figure 1). The
demographic andmetabolic characteristics of the individualswith
T2D are displayed in Table 1. Among the samples, 14 biopsies
(47%) from individuals with T2D and DN, but none of those
obtained from controls, were positive for podocyte B7-1 ex-
pression (Figure 1, A, C, and D). Accordingly, real-time PCR on
kidney biopsies showed increased B7-1 mRNA expression in in-
dividuals with T2D compared with controls (Figure 1B). To an-
alyze B7-1 expression in our cohort of individuals with T2D, we
divided our sample group based on a recently proposedDNpath-
ologic classiﬁcation.13 One individual with class 1 DN lesions
showed high B7-1 expression (17% of the class 1 DN group)
(Figure 1D), whereas individuals with class 2A–2B DN lesions
showed moderate (25% of the class 2A–2B DN group) to high
(25%of the class 2A–2BDN group) B7-1 expression (Figure 1D).
Among individuals with T2D and DN class 3 renal pathologic
evidence, 43% and 14% within this group showed moderate and
high B7-1 expression, respectively (Figure 1D). Finally, the only
patient with T2D classiﬁed as DN class 4 displayed high B7-1
expression (Figure 1D). Anecdotal cases of kidney biopsies with
different degrees of glomerular B7-1 expression in individuals
with T2D and various types of renal lesions are provided in Figure
1, E1–E5. Notably, high B7-1 expression levels parallel pro-
gressively reduced expression of synaptopodin, a cytoskeleton-
associated podocyte-speciﬁc protein14,15 (Figure 1, F1–F5). This
overlap with synaptopodin suggested podocyte localization of
B7-1 (Figure 1, G1–G5; see Supplemental Table 1 for the list of
antibodies used). B7-1 is thus upregulated in renal glomeruli from
individuals with T2D and with different degrees of DN-related
lesions.
Plasma Concentrations of sCD28 Determined at
Baseline Are Associated with Future Risk of ESRD:
Univariate and Multivariate Analyses
The soluble CD28 (B7-1 soluble ligand), a 44-kDprotein, present
in the peripheral bloodstream may be responsible for triggering
podocyte B7-1. Interestingly, baseline plasma concentration of
sCD28 was signiﬁcantly higher in individuals who subsequently
developed ESRD compared with individuals with preserved renal
function (Supplemental Table 2). Nonparametric correlation co-
efﬁcients of sCD28 with relevant baseline clinical characteristics
were as follows: hemoglobin A1c (HbA1c),20.02; albumin cre-
atinine ratio (ACR), 0.25; and eGFR, 20.13. We then examined
the incidence rates of ESRD according to the quartiles of distri-
bution of peripheral concentrations of sCD28 at baseline.Highest
ESRD rates were observed among participants with high sCD28
concentrations, ESRD incidence rates were as follows: 1.7 for
quartile 1 (Q1), 3.3 for Q2, 3.2 for Q3, and 6.0 for Q4 per 100
patient-years (P value for trend, P=0.003) (Figure 2A). When we
examined the temporal pattern of ESRD occurrence according to
baseline plasma concentrations of sCD28, the cumulative risk of
ESRD for the highest quartile of sCD28 reached 66% within 12
years of follow-up, whereas it was 25%–38% for the remaining
quartiles (P value for trend, P=0.01) (Figure 2B). None of the
aforementioned results were evident across the quartiles of soluble
B7-1 (sB7-1) distribution (data not shown). In a logistic regression
model, the odds ratio (OR)of the subsequentprogression toESRD
for individuals with high baseline concentrations of sCD28 (Q4)
was 5.5 (95%conﬁdence interval [95%CI], 2.0 to 14;P=0.001). In
themultivariate analysis adjusted for clinical covariates at baseline,
such as age, eGFR, HbA1c, and albuminuria (all of them as con-
tinuous variables), the independent ratio of odds of progression to
ESRDamong individualswith high concentrations of sCD28 (Q4)
was 2.8 (95% CI, 1.0 to 7.8; P=0.04) (Figure 2C). The OR for
sCD28 Q4, using a model with the same clinical covariates con-
sidered but including only patients followed for at least 5 years, was
4.8 (95% CI, 1.4 to 16; P=0.01). An increase in sCD28 peripheral
levels may trigger podocyte B7-1, thus accelerating the decline in
kidney function in individuals with T2D and DN.
B7-1 Is Upregulated in Podocytes in High Glucose
Conditions In Vitro
Podocytes were cultured in vitro in the presence of normal
glucose (NG) or high glucose (HG) for 7 and 14 days and
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B7-1 expression was evaluated by FACS analysis. Less than 2%
of podocytes expressed B7-1 when cultured in NG for 14 days
(Figure 3, A and H). Our results showed that 18% and 37% of
podocytes were positive for B7-1 after 7 and 14 days of the HG
condition, respectively, compared with NG and mannitol
(serving as the osmotic control) (Figure 3, A and H). Notably,
podocytes did not express other costimulatory molecules in
any of the conditions (Figure 3, B–G). Real-time PCR and
Western blot analysis conﬁrmed the increase of B7-1 mRNA
and protein in podocytes cultured during HG conditions (Fig-
ure 3, I and J). B7-1 had perinuclear, cytoplasmic, and cellular
process localization on immunoﬂuorescence (Figure 3, L and
M), whichwas absent in podocytes cultured inNG (Figure 3K)
and mannitol (data not shown). Coexpression of B7-1 and
Figure 1. B7-1 is upregulated in kidney biopsies obtained from a subset of patients with T2D and DN-related lesions. Kidney biopsies
obtained from individuals with T2D. (A, C, and D) B7-1 is expressed in 47% of biopsies obtained from individuals with T2D. (B) Real-time PCR
analysis conﬁrms an upregulation of B7-1 mRNA expression in individuals with T2D compared with controls (*P,0.05). (D) Results show that
17% of individuals with T2D and belonging to DN class 1 have high B7-1 expression, whereas individuals with class 2A–2B DN lesions show
moderate (25%) to high (25%) B7-1 expression. Among individuals with T2D and in DN class 3, 43% and 14% show a moderate and high
B7-1 expression, respectively. Finally, the individual with T2D belonging to DN class 4 displays high B7-1 expression. (E1–E5) Anecdotal
cases of kidney biopsies with different degrees of glomerular B7-1 expression in individuals with T2D and various types of renal lesions.
(F1–F5) Notably, high B7-1 expression levels are paralleled by a progressively reduced expression of synaptopodin. (G1–G5) This overlap
with synaptopodin suggests podocyte localization of B7-1. Ctrl, control; glom, glomerulus. Original magniﬁcation, 3200.
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Table 1. Demographic and metabolic characteristics of individuals with type 2 diabetes who underwent kidney biopsy
Patient
Age
(yr)
Sex
DD
(yr)
Creatinine
(mg/dl)
UAE
(mg/dl)
BUN
(mg/dl)
GFR
(ml/min)
HbA1c
(%)
Cholesterol
(mg/dl)
Triglycerides
(mg/dl)
SBP
(mmHg)
DBP
(mmHg)
B7-1
(AU)
1 61 Man 2 1.6 2.1 59 59 6.2 260 201 140 80 2
2 59 Man 3 1.3 1.0 66 40 5.4 213 99 140 80 0
3 44 Man 1 0.9 0.7 35 150 7.1 168 185 120 70 2
4 65 Man 17 2.1 4.3 68 38 6.3 231 114 140 90 0
5 63 Man 2 0.9 1.7 38 57 5.5 254 158 110 80 0
6 65 Man 12 0.7 3.4 25 114 8.9 267 195 150 80 1
7 77 Woman 4 0.7 2.3 36 120 5.2 160 100 160 90 2
8 48 Man 17 1.1 19.8 45 89 8.4 190 182 135 80 1
9 79 Man 4 2.4 1.6 67 40 5.9 250 180 140 60 0
10 54 Man 13 1.0 9.0 43 90 10.1 333 279 160 90 1
11 64 Man 5 1.2 0.6 41 108 8.0 151 188 150 80 1
12 65 Woman 10 1.1 4.8 78 54 7.6 230 484 140 80 0
13 64 Man 7 1.2 1.2 76 59 8.9 280 190 160 90 1
14 50 Man 3 1.1 2.0 38 100 8.1 241 314 150 90 2
15 59 Man 30 1.7 6.0 48 29 9.2 347 550 120 60 0
16 67 Man 20 1.5 6.0 39 98 8.2 195 263 140 70 1
17 56 Man 5 1.2 1.2 56 64 8.7 229 92 150 80 1
18 72 Woman 39 1.1 1.0 77 58 9.3 282 99 140 70 0
19 67 Man 14 1.2 2.0 41 58 6.4 224 138 145 90 0
20 58 Man 7 1.8 1.0 77 58 7.4 338 452 140 80 1
21 57 Man 7 1.1 2.9 34 84 7.9 161 302 150 90 2
22 46 Man 6 0.8 0.9 52 58 7.8 177 106 160 90 0
23 59 Man 20 1.1 1.9 45 49 7.5 151 85 150 90 0
24 40 Man 4 0.7 1.0 38 98 6.9 194 193 130 80 2
25 59 Man 3 0.9 0.4 41 102 8.3 200 150 120 80 0
26 59 Man 33 1.4 0.6 82 44 7.5 221 158 140 90 0
27 58 Man 4 1.2 0.8 50 98 7.6 155 109 140 90 0
28 61 Man 6 1.1 0.5 45 76 7.4 160 120 140 90 0
29 59 Man 6 1.2 0.6 43 90 7.2 140 98 130 80 0
30 62 Woman 32 1.8 4.0 65 17 8.0 350 480 130 70 0
DD, disease duration; SBP, systolic BP; DBP, diastolic BP; AU, arbitrary unit.
Figure 2. Elevated baseline plasma concentrations of sCD28 are associated with future risk of ESRD. (A) ESRD incidence rates are shown
according to quartile distribution for the baseline plasma levels of soluble CD28 (sCD28). Low baseline sCD28 concentrations result in
low ESRD incidence rates, whereas a progressive increase of marker concentration in the serum is associated with worse outcome.
Incidence rates according to quartile distribution are as follows: Q1, 1.7; Q2, 3.3; Q3, 3.2; and Q4, 6.0 per 100 patient-years (**P,0.01).
(B) The cumulative risk for ESRD occurrence for Q4 of sCD28 reaches 66% within 12 years of follow-up, whereas it is 25%–38% for the
remaining quartiles (*P,0.05). (C) In a logistic regression model, the OR of the subsequent progression to ESRD for participants with
high baseline concentrations of sCD28 (Q4) is 5.5 (95% CI, 2.0 to 14; ***P=0.001). Multivariate analysis adjusted for clinical covariates at
baseline, such as age, eGFR, HbA1c, and albuminuria, shows an odds of progression ratio to ESRD of 2.8 (95% CI, 1.0 to 7.8; *P=0.04)
among patients with high concentrations of sCD28 (Q4).
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synaptopodin suggested the podocyte origin of B7-1 (Figure 3,
N–P). B7-1 is upregulated in podocytes in HG conditions.
B7-1 Upregulation Is Phosphatidylinositol 3-Kinase
Dependent
The pathway that regulates B7-1 expression in podocytes in
response to HG is largely unknown5; elucidation of this path-
way may provide novel therapeutic targets and may conﬁrm
the common pathway between HG and B7-1 upregulation.
Three major intracytoplasmic key players appeared to be po-
tentially related to both HG intracellular signaling and B7-1
expression: phosphatidylinositol 3-kinase (PI3K), serine/thre-
onine protein kinase (AKT), and glycogen synthase kinase 3
(GSK3).16,17 AR-A014418 (0.2–2 mM) and triciribine (1–10
mM) (GSK3 and AKT inhibitors, respectively) did not affect
B7-1 expressionwhen added to podocytes cultured duringHG
Figure 3. B7-1 is upregulated in podocytes in HG conditions in vitro. Conditionally immortalized podocytes are grown at 37°C in NG
(10 mM) and HG (30 mM) for 7 and 14 days (D). Mannitol (20 mM plus glucose 10 mM) is used as an osmotic control. Cells are harvested,
and the expression of multiple costimulatory molecules is evaluated by FACS analysis. B7-1 is barely expressed after 14 days of normal
glucose or mannitol (A and H) culture conditions, whereas it increases after 7 and 14 days of HG conditions (*P,0.05; ***P,0.001,
NG versus HG, 7D and HG14D, respectively; ***P,0.001, mannitol versus HG 14D). (B–G) All other costimulatory molecules tested are
unchanged during HG. (I) Real-time PCR analysis conﬁrms the increase of B7-1 mRNA after 7 and 14 days in high glucose compared
with normal glucose (*P,0.05; **P,0.01, NG versus HG 7D and HG 14D; **P,0.01, HG 7D versus HG14D). (J) Similarly, Western blot
analysis shows greater B7-1 expression in podocytes cultured in HG after 14 days compared with those cultured in NG. (K–M) Im-
munoﬂuorescence analysis conﬁrms B7-1 expression in podocytes after 7 and 14 days of HG (L and M), but not after NG (K), conditions.
(N–P) B7-1 is expressed on podocytes as shown by colocalization with synaptopodin, an actin-associated protein. To determine the
pathway linking HG and B7-1 upregulation, we tested the effect of AKT, GSK3, and PI3K inhibitors on B7-1 expression. (Q) Although
the AKT (triciribine) and GSK3 (AR-A014418) inhibitors are ineffective in downregulating B7-1 expression, the pan-PI3K inhibitor
quercetin inhibits B7-1 upregulation (***P,0.001, 10 and 100 mM quercetin versus HG). (R) Western blot analysis shows higher levels of
phosphorylation of the p85 PI3K subunit and an increase in expression of the p110a subunit upon HG culture, conﬁrming the increased
activity of the PI3K pathway after high glucose exposure. The PI3K inhibitor quercetin reduces both p85 phosphorylation and p110a
levels. (S) A more speciﬁc pan-PI3K inhibitor (LY29009) downregulates B7-1 expression as well (*P,0.01; ***P,0.001, HG versus
LY29009 4 and 40 mM, respectively). Only the speciﬁc targeting of the p110a PI3K subunit with PIK-75 (4–40 nM), but not of p110b and
p110g with TGX-221 (5–50 nM) and AS605240 (5–50 nM) respectively, was able to downregulate HG-dependent B7-1 expression in
HG-cultured podocytes (***P,0.001, HG versus PIK-75 4–40 nM). ab, antibody; PD-L1, programmed cell death ligand 1; PD-L2, pro-
grammed cell death ligand 2; ICOSL, inducible costimulator ligand; phospho, phosphorylated; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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for 14 days, despite demonstration of inhibition of GSK3 and
AKT activity (Figure 3Q and data not shown). Conversely,
quercetin (10–100 mM), a pan-PI3K inhibitor, was effective
in reducing B7-1 expression in HG conditions (Figure 3Q).
Western blot analysis revealed that in HG conditions, expres-
sion of the 110-kD catalytic PI3Ka subunit (p110a) was in-
creased and phosphorylation of the regulatory subunit p85
was decreased compared with NG condition (Figure 3R and
data not shown). A more speciﬁc PI3K inhibitor (LY29009),
used for a shorter period of time and at different doses (4–40
mM) to avoid toxicity, was also effective in reducing B7-1
expression after 7 days of treatment (Figure 3S). We then con-
ﬁrmed the role of the p110a subunit by using selective inhib-
itors of p110a (PIK-75, 4–40 nM), p110b (TGX-221, 5–50
nM), and p110g (AS605240, 5–50 nM) PI3K subunits. Only
the p110a-speciﬁc inhibitor was able to inhibit HG-dependent
B7-1 upregulation (Figure 3S).HG-dependent B7-1 upregulation
is mediated by the speciﬁc activation of the 110-kDa catalytic
PI3Ka subunit.
CTLA4-Ig Prevents HG-Induced Podocyte Cytoskeleton
Disruption In Vitro
We examined the effect of CTLA4-Ig on HG-induced podocyte
cytoskeleton abnormalities by immunoﬂuorescence analysis.
First, we were able to show that CTLA4-Ig, but not L6, binds
to B7-1 on podocytes in vitro (Figure 4, A–D, Supplemental Ma-
terial). Second, we observed that during CTLA4-Ig treatment,
B7-1 appeared barely expressed upon immunoﬂuorescence anal-
ysis in podocytes cultured in HG (Figure 4E4); however, B7-1
protein was detectable byWestern blot, conﬁrming that CTLA4-
Ig was possibly masking B7-1 epitopes (Figure 4E4, inset). Fur-
thermore, CTLA4-Ig, but not L6, prevented the HG-induced
alteration of synaptopodin (Figure 4, E1–E4). Actin staining by
phalloidin showedmicroﬁlament depolarization and signs of cy-
toskeleton derangement in HG, whereas CTLA4-Ig, but not L6,
preserved actin and paxillin (a focal adhesion–associated protein
activated after integrin-dependent cell adhesion18) original struc-
tures (Figure 4, F1–F4). a3b1 integrin (a protein that physiolog-
ically participates in slit diaphragm formation and integrity19)
activation is preserved by CTLA4-Ig but not L6 (Figure 4, G1–
G4). Podocyte motility, assessed by an in vitro wound healing
assay, was increased in podocytes exposed toHGconditions (Fig-
ure 4, I1, I2, and K) compared with podocytes cultured in NG
(Figure 4, H1, H2, and K) and CTLA4-Ig therapy was able to
prevent podocyte migration (Figure 4, J1, J2, and K). Finally,
quantiﬁcation of actin stress ﬁbers further conﬁrmed the de-
rangement of the structure of the actin ﬁlaments in HG-cultured
podocytes and the therapeutic effect of CTLA4-Ig (Figure 4, L1–
L3 and M). Importantly, CTLA4-Ig prevented cytoskeleton and
adhesion abnormalities in podocytes exposed to HG in vitro.
B7-1 Overexpression Induces Podocyte Morphologic
Abnormalities
To clarify whether the overexpression of B7-1 or gene silencing
of B7-1 expression in podocytes was able to mimic the effect of
HG and the protection mediated by CTLA4-Ig, we genetically
upregulated and downregulated B7-1 expression. Podocytes
were transducedwithdifferent lentiviral vectors carryingeither
theB7-1cDNAsequence (VVWP–B7-1orB7-1–overexpressing
podocytes) or a speciﬁc small hairpin RNA (shRNA) se-
quence (pLKO.1-shRNA or B7-1 knockdown podocytes).
B7-1 overexpression and downregulation were assessed by
FACS and by Western blot analyses (Figure 5, A, B, E, and F).
In NG and HG conditions (7 days), B7-1–overexpressing
podocytes (.95% of B7-1+ podocytes; Figure 5A) showed a
loss of synaptopodin staining in immunoﬂuorescence analysis
compared with wild-type (WT) podocytes. CTLA4-Ig therapy
was able to prevent these alterations (Figure 5, C1–C3). Elec-
tron microscopy analysis showed an altered cellular morphol-
ogy with dilated reticulum cisternae (Figure 5D2, red arrow)
and numerous glycogen particles (Figure 5D2, white arrow) in
the VVWP–B7-1 podocytes compared with WT (Figure 5, D1
and D2) and CTLA4-Ig–treated (Figure 5D3) podocytes. Con-
versely, pLKO.1 podocytes were similar to WT podocytes in
terms of conserved synaptopodin expression (Figure 5, G1 and
G2) and cellular ultrastructure (Figure 5, H1 and H2) when
cultured in HG, whereas CTLA4-Ig did not exert any appre-
ciable activity (Figure 5, G3 and H3). Transduction with
VVWP–B7-1 and pLKO.1 control vectors did not modify po-
docyte morphology or ultrastructure compared with WT con-
ditions (data not shown).
B7-1 Promotes Podocyte Cell Death
To better determine the role of the modulation of B7-1
expression on podocyte survival, we studied the effect of
genetic overexpression and downregulation of B7-1 on podo-
cyte apoptosis. B7-1–overexpressing podocytes cultured in
NG (data not shown) andHG conditions for 7 days had higher
apoptotic events compared with WT podocytes (Figure 5I),
whereas podocytes in which B7-1 expression was downregu-
lated had lower apoptosis rates compared with VVWP–B7-1
and similar apoptotic events to WT podocytes (Figure 5J).
Finally, infection with VVWP–B7-1 and pLKO.1 control vec-
tors, did not modify the percentage of apoptotic podocytes
compared with WT cells (Figure 5, I and J).
B7-1 Induction Promotes Degradation of
Synaptopodin and Loss of Stress Fibers
To explore a link between B7-1 expression and podocyte
cytoskeleton disruption, we exposed podocytes to LPS, an
established inducerof podocyte B7-1 expression.5 Inductionof
B7-1 expression caused degradation of synaptopodin (Figure
5K) and the loss of stress ﬁbers in WT but not in B7-1 knock-
down podocytes (Figure 5, L1–L3). Gene silencing of B7-1
preserved synaptopodin protein abundance and stress ﬁber
integrity (Figure 5, K and L3).
Podocyte B7-1 Is Induced in Two Models of DN In Vivo
We evaluated podocyte B7-1 expression in vivo in two models
of DN.20 A progressive increase in B7-1 expression was
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observed in the glomeruli of leptin-deﬁcient db/db mice with
established DN compared with controls during follow-up
(Figure 6, A1–A4 and B). Kidneys obtained from chemically-
induced (via streptozotocin injection) hyperglycemic C57BL/6
mice were negative for B7-1 expression at 7 weeks of age (base-
line) immediately after streptozotocin injection, whereas B7-1
expression was evident at 12 and 16 weeks of age (Figure 6, D1–
D4 and E).
CTLA4-Ig Ameliorates Urinary Albumin Excretion in
Diabetic Mice In Vivo
At 7weeks of age, whenhyperglycemia but notDNwas present,
db/db and streptozotocin-injected C57BL/6 were treated with
CTLA4-Ig or L6 as follows: 500 mg induction regime at day 0;
250 mg at days 2, 4, 6, 8, and 10; and 250 mg twice a week until
day 30. This dosage has been shown to inhibit B7-1 in a model
of in vivo LPS-stimulated dendritic cell activation12 as well as
Figure 4. B7-1 activation leads to abnormalities of podocyte morphology and motility. (A and B) Podocytes cultured for 14 days in HG,
untreated, or treated with CTLA4-Ig or L6 (100 mg/ml) are harvested and stained with FITC-conjugated anti-mouse IgG. Unstained,
untreated, and L6-treated podocytes are not differentially stained by the FITC-conjugated anti-mouse IgG, but increased anti-murine–IgG-
FITC staining is evident in podocytes treated with CTLA4-Ig (**P,0.01; *P,0.05, anti-murine–IgG-FITC+CTLA4-Ig versus unstained, anti-
murine–IgG-FITC untreated and anti-murine–IgG-FITC+L6, respectively). (C and D) CTLA4-Ig binding, but not L6, is conﬁrmed by indirect
immunoﬂuorescence with anti-murine–IgG-FITC. (E1–E4, F1–F4, G1–G4) Morphologic analysis of podocytes cultured in NG shows normal
cytoskeleton organization (E1, F1, and G1); however, after HG exposure, severe actin depolymerization (red), synaptopodin (red), and
paxillin (green) degradation as well as activated a3b1 integrin (red) disruption are evident along with B7-1 upregulation (green) (E2, F2, and
G2). CTLA4-Ig treatment (E4, F4, and G4), but not L6 (E3, F3, and G3), normalized most podocyte cytoskeleton abnormalities induced by
HG. (H1, H2, I1, I2, and K) Podocytes exposed to HG for 48 hours display increased motility compared with podocytes cultured in NG
(**P,0.01, NG versus HG). (I1, I2, J1, J2, and K) CTLA4-Ig therapy prevented podocyte migration (**P,0.01, HG versus CTLA4-Ig). (L1, L2,
and M) HG-cultured podocytes show derangement of actin ﬁlaments compared with NG control podocytes (***P,0.001, NG versus HG).
(M) CTLA4-Ig is able to reinstate stress ﬁber integrity (**P,0.01, HG versus CTLA4-Ig). Original magniﬁcation, 3400.
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in an in vivo model of chronic rejection.21 Although urinary
albumin excretion increased in diabetic untreated db/db mice
and L6-treated db/db mice (100 mg/ml; Figure 6C), urinary
albumin excretion remained stable over time in CTLA4-Ig–
treated db/db mice (Figure 6C). In a second murine model of
DN (streptozotocin-injected C57BL/6 mice), an increase in
urinary albumin excretion was shown in diabetic untreated
mice and L6-treated mice (Figure 6F) but not in CTLA4-Ig–
treated mice (Figure 6F). No increase in urinary albumin ex-
cretion was observed in nondiabetic control mice (Figure 6, C
and F). We excluded the presence of any B7-1 tubular staining
in db/db mice aged 7, 12, and 25 weeks (Figure 6, G1–G3) and
demonstrated complete overlapping of B7-1 and the podocyte
protein ZO-1 expression in db/db mice (Figure 6, H1–H3).
Similarly, the percentage of mesangial expansion, another im-
portant feature of DN, increased in 25-week-old diabetic
Figure 5. B7-1 genetic modulation impacts on podocyte morphology and survival. Podocytes are transduced with lentiviral vectors
carrying either the B7-1 cDNA sequence (VVWP–B7-1 or B7-1–overexpressing podocytes) or a speciﬁc shRNA sequence (pLKO.
1-shRNA or B7-1 knockdown podocytes). (A, B, E, and F) Successful transduction is assessed by FACS (A and E) and by Western blot
analyses (B and F). (C1–C3 and D1–D3) Morphologically, VVWP–B7-1 podocytes showed a loss of synaptopodin staining (C2) with
dilated reticulum cisternae (D2, red arrow) and glycogen particles (D2, white arrow) compared with WT (C1 and D1) and CTLA4-Ig–
treated podocytes (C3 and D3). (G1–G3 and H1–H3) Downregulation of B7-1 using the pLKO.1-shRNA viral vector generates cell
features comparable to WT podocytes with regard to synaptopodin degradation (G1–G3) and ultrastructural alterations (H1–H3). (I)
VVWP–B7-1 podocytes display higher apoptotic events compared with WT podocytes (*P,0.05, WT versus VVWP–B7-1). (J) pLKO.
1-shRNA podocytes show levels of apoptosis comparable to WT podocytes. (I and J) Apoptosis is unmodiﬁed in podocytes transduced
with control lentiviral vectors. (K) The LPS-induced degradation of synaptopodin is prevented in B7-1 knockdown podocytes. (L1)
Double labeling for actin (red) and B7-1 (green) shows well developed stress ﬁbers and absence of B7-1 in WT podocytes. (L2 and L3)
The LPS-induced upregulation of B7-1 and the loss of stress ﬁbers (L2) are prevented in B7-1 knockdown (B7-1-shRNA) podocytes (L3).
ab, antibody; IF, immunoﬂuorescence; EM, electron microscopy; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Figure 6. B7-1 immunoﬂuorescence is performed in kidneys of two different murine models of DN. No B7-1 expression is observed in
kidneys of control nondiabetic (Ctrl ND) heterozygous littermate db/db mice (A1 and B), whereas progressively increased B7-1 ex-
pression is noted in kidneys of 7-, 12- and 25-week-old db/db mice (A1–A4 and B) (*P,0.05; ***P,0.001, control versus 12 and 25
weeks, respectively; **P,0.01, 7 weeks versus 25 weeks). Db/db mice are randomly allocated to receive treatment with L6 (n=25) or
CTLA4-Ig (n=25). (C) Signiﬁcantly higher UAE levels are evident at 7, 12, and 25 weeks of age in db/db L6-treated mice and diabetic
untreated db/db mice compared with controls (*P,0.05, control versus L6-treated mice and CTLA4-Ig–treated mice at 7 weeks;
**P,0.01, control versus untreated and L6-treated mice at 12 weeks; ***P,0.001, control versus untreated and L6-treated mice at 25
weeks). On the contrary, UAE levels remain stable over time in CTLA4-Ig–treated mice (***P,0.001, CTLA4-Ig versus untreated and L6-
treated mice at 25 weeks). (D1, D2, and E) Absent B7-1 expression is observed in control C57BL/6 mice (7 weeks of age) (D1 and E) and
in 7-week-old hyperglycemic C57BL/6 mice immediately after streptozotocin injection (D2 and E). (D3 and D4 and E) An increase in B7-1
expression is detected in 12- and 16-week-old hyperglycemic C57BL/6 mice after streptozotocin injection (***P,0.001, control versus
12 and 16 weeks; ***P,0.001, 7 weeks versus 12 and 16 weeks). (F) Untreated diabetic C57BL/6 mice and L6-treated C57BL/6 mice
show higher UAE at 12 and 16 weeks of age compared with control mice (**P,0.01, control versus untreated and L6-treated mice at 12
weeks; ***P,0.001, control versus untreated and L6-treated mice at 16 weeks). Conversely, UAE levels remained stable over time in
CTLA4-Ig–treated mice (**P,0.01; *P,0.05, CTLA4-Ig versus untreated and L6-treated mice at 16 weeks, respectively). Kidney pa-
renchyma immunoﬂuorescence showed absence of tubular B7-1 expression (G1–G3) and colocalization of B7-1 with ZO-1 (H1–H3) in
db/db mice, demonstrating the podocyte localization of B7-1. Low levels of mesangial expansion are detectable in control nondiabetic
C57BL/6 mice at 7 and 25 weeks of age (#P,0.05, control versus all) (I1, I2, and I7) and in untreated db/db mice at 7 weeks of age (I3
and I7). (I3–I5 and I7) Conversely, increased mesangial expansion is evident at 25 weeks of age in untreated and L6-treated diabetic db/
db mice compared with untreated db/db mice at 7 weeks of age (***P,0.001, db/db: untreated [7 weeks] versus untreated [25 weeks]
and L6-treated mice). (I4–I7) CTLA4-Ig–treated diabetic db/db mice have lower mesangial expansion compared with untreated and L6-
treated diabetic db/db mice at 25 weeks of age (**P,0.01; *P,0.05, CTLA4-Ig–treated versus untreated [25 weeks] and L6-treated
mice, respectively). Original magniﬁcation, 31000 in G1–G3 and H1–H3; 3250 in I4–I7.
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untreated mice and L6-treated mice compared with 25-week-
old nondiabetic and CTLA4-Ig–treatedmice (Figure 6, I1–I7).
CTLA4-Ig also reduces collagen I deposition (Figure 7, A1–
A4), preserves podocytes and nephrin/ZO-1 expression (Fig-
ure 7, B1–B4 and C1–C4, respectively), and reduces glomerular
active caspase 3–positive (Figure 7, D1–D4) and terminal deoxy-
nucleotidyl transferase–mediated digoxigenin-deoxyuridine
nick-end labeling–positive nuclei (Figure 7, E1–E4) in db/db
mice aged 25 weeks in vivo compared with L6-treated or un-
treated diabetic mice at the same time point. The aforemen-
tioned effects are obtained without affecting peripheral serum
glucose (Figure 7F), creatinine (Figure 7G), and cytokine levels
(Figure 7, H–J).
Two Single Nucleotide Polymorphisms of the B7-1
Gene Are Associated with the Progression of DN to
ESRD
To conﬁrm that the B7-1/CD28 axis is relevant for DN in
humans, we used samples from the Joslin Study of Genetics of
Nephropathy in individuals with T2D (Supplemental Figure 1,
Supplemental Table 3). This cohort is composed of individuals
with T2Dmonitored for 8–12 years of follow-up and censored
for decline in renal function, onset of proteinuria, and ESRD.
To evaluate whether any polymorphism in the B7-1 gene could
affect DN onset or progression, we screened and genotyped
173 individuals with T2D, DN, and either microalbuminuria
(n=3), proteinuria (n=138), or ESRD (n=32) as well as 177
normoalbuminuric individuals. Genotypic associations with
DN, ACR, and eGFR for single-nucleotide polymorphisms
(SNPs) genotyped across the B7-1 locus are shown in Supple-
mental Tables 3 and 4. The strongest association with the pro-
gression to ESRD, or with the worsening of ACR and decline in
eGFR, in this population occurred at rs2629396 (OR, 1.56;
P=0.01), a SNP located in intron 4 (position IVS4-183) of
the B7-1 gene (Supplemental Figure 1, A–C, Supplemental
Table 3). A comprehensive analysis of imputed SNPs across
this region identiﬁed a strong association at a second SNP
(rs1523311) in complete linkage disequilibrium (r2=1.0)
with rs2629396 and located in intron 5 of B7-1 (position
IVS5+388) (Supplemental Table 4). Although these data
highly suggest the relevance of B7-1 in the progression of
DN to ESRD, these associations did not achieve statistical sig-
niﬁcance when a conservative Bonferroni correction was ap-
plied (threshold for signiﬁcance: 0.05/12=0.00042; corrected
P=0.01). None of the SNPs evaluated at the CD28 locus were
shown to be associated with ESRD, ACR, or eGFR.
DISCUSSION
DN is a serious complication faced by individuals with T1 and
T2D.1,2,22 Despite the extensive use of angiotensin-converting
enzyme inhibitors and renin-angiotensin system blockers and
the overall improvement in glycemic and BP control thera-
pies, the burden of DN has not declined and DN remains a
primary cause of ESRD onset.23,24 Several of the recently
tested approaches have failed to provide clear beneﬁts,25–29
whereas others have offered such a narrow therapeutic win-
dow30 that the pursuit for novel therapeutic approaches is
necessary.
Our data show that B7-1 expression represents a common
response of podocytes toHGandhyperglycemia, given thatB7-
1 is upregulated in podocytes in vitro, in hyperglycemicmice in
vivo, and in individuals with T2D. Our results showed that
47% of individuals with T2D had B7-1 expression; however,
the upregulation of podocyte B7-1 expression was evident in
the early phase of DN, whereas B7-1 was mainly absent in
individuals with T2D and diffused glomerulosclerosis. It is
possible that B7-1 positivity deﬁnes a subgroup of individuals
with T2D, proteinuria, and altered GFR, thus reconciling the
dichotomy between proteinuria and decline in GFR that is
found in some individuals with T2D and DN. Under the latter
hypothesis, the presence of B7-1 may indeed deﬁne a group of
individuals at higher risk for the progression of DN.
Genetic and epidemiologic analyses conﬁrmed the rele-
vance of B7-1 for DN.We identiﬁed two SNPs of the B7-1 gene
(rs2629396 and rs1523311), which appeared to be correlated
with DN incidence, with the worsening of ACR and decline of
eGFR over time. These two SNPs of the B7-1 gene are located
in two intron regions (4 and 5) of chromosome 3, which may
constitute a DN-susceptible locus. Baseline plasma concentra-
tions of soluble CD28 (the natural ligand of B7-1) were mark-
edly increased in individuals who subsequently developed
ESRD; indeed, it is possible, although unproven by our data,
that soluble CD28 may trigger B7-1 activation on podocytes,
thus leading to morphology abnormalities, including marked
alteration of cytoskeleton structure. The genetic and epidemi-
ologic analysis of the Joslin cohort of individuals with T2D
establish the blueprint that the B7-1/sCD28 axis is relevant for
the progression of DN. The upregulation of B7-1 expression in
podocytes is speciﬁc and is not the result of a global increase of
all costimulatory molecules due to inﬂammation, because
B7-1 is the only costimulatory molecule upregulated on po-
docytes in HG conditions, possibly through a PI3K p110a-
dependent mechanism. B7-1 upregulation may per se induce
podocyte cytoskeleton abnormalities, as suggested by our B7-1
genetic modulation studies.
Finally, according to our peripheral cytokine proﬁling and
our in vitro podocyte studies, CTLA4-Ig action seems to take
place independently of any anti-inﬂammatory or immuno-
modulatory effect, but, rather, through a podocyte-speciﬁc
protective mechanism that ultimately prevents cellular abnor-
malities. Interestingly, drugs targeting B7-1 (CTLA4-Ig) are
available for treating autoimmune diseases and in kidney
transplantation (e.g., abatacept and belatacept).11 Multiple tri-
als based on CTLA4-Ig are currently ongoing,31,32 with almost
2000 individuals already treated and an overall rate of side
effects comparable to the placebo arm.11,33 We acknowledge
that different limitations are present in our study. First, we did
not demonstrate a major salutary effect of CTLA4-Ig on DN.
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Second, the use of better models of diabetic glomerulopathy
would have been potentially more meaningful. The lack of
major differences noted in glomerular basal membrane thick-
ness and in the number of WT1+ cells among groups (Supple-
mental Figure 3A) may be related to the less than severe DN
that occurs in db/db mice. Unfortunately, the few remaining
murine models of DN (e.g., OVE26 mice) may not be
appropriate for the study of B7-1 expression. Although the
OVE26 mouse expresses a chicken calmodulin minigene con-
trolled by the rat insulin II promoter and develops severe DN
within weeks after birth,34 we were not able to detect any B7-1
expression in the glomeruli of OVE26 mice. This absence of
B7-1 expression could be due to the presence of a high-afﬁnity
binding site for calmodulin on PI3K,35 so thatmanipulation of
Figure 7. Morphologic and immunoﬂuorescence analyses are performed on kidney samples obtained from untreated 7-week-old or
from 25-week-old L6-treated mice or CTLA4-Ig–treated mice. Collagen I deposition is increased in L6-treated compared with CTLA4-
Ig–treated and 7-week-old untreated db/db mice (**P,0.01, L6-treated mice at 25 weeks versus 7 weeks) (A1–A4), nephrin (*P,0.05,
L6-treated mice at 25 weeks versus CTLA4-Ig–treated mice at 25 weeks) (B1–B4), and ZO-1 (*P,0.05, L6-treated mice at 25 weeks
versus CTLA4-Ig–treated mice at 25 weeks) (C1–C4) expression is preserved in CTLA4-Ig–treated mice compared with those treated
with L6. (D1–D4) Increased expression of glomerular active caspase 3 is also evident in L6-treated mice compared with CTLA4-Ig–
treated mice and 7-week-old untreated db/db mice (*P,0.05, L6-treated mice at 25 weeks versus CTLA4-Ig–treated mice at 25 weeks
and untreated mice at 7 weeks). (E1–E4) TUNEL staining shows higher levels of apoptosis in 25-week-old L6-treated mice compared
with 7-week-old untreated mice (*P,0.05, L6-treated mice at 25 weeks versus untreated mice at 7 weeks). (F and G) Serum glucose and
creatinine levels are not different between 12 and 25 weeks of age between L6-treated mice and CTLA4-Ig–treated db/db mice
(P=NS). (H–J) Peripheral levels of Th1 cytokines are increased over time in both L6-treated mice (*P,0.05, IL-2: L6-treated mice at 25
weeks versus 12 weeks; ***P,0.001; **P,0.01, IFN-g: L6-treated mice at 25 weeks versus 12 and 7 weeks, respectively) and CTLA4-Ig–
treated db/db mice (*P,0.05, IL-2: CTLA4-Ig–treated mice at 25 weeks versus 12 weeks; *P,0.05, IFN-g: CTLA4-Ig–treated mice at 25
weeks versus 12 weeks; *P,0.05, TNF-a: CTLA4-Ig–treated mice at 25 weeks versus 12 weeks). TUNEL, terminal deoxynucleotidyl
transferase–mediated digoxigenin-deoxyuridine nick-end labeling; nucl, nuclei; glom, glomeruli. Original magniﬁcation, 3630 in A1–
A4, B1–B4, C1–C4; 3400 D1–D4.
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calmodulin may interfere with PI3K activity and ultimately
with B7-1 expression.35
In conclusion, HG and hyperglycemia elicit B7-1 activation
on podocytes, thereby potentially creating a therapeutic plat-
form for the use of speciﬁc B7-1–targeting strategies for the
treatment of proteinuria in DN (Figure 8) as shown by our
recent ﬁndings showing the efﬁcacy of Abatacept (CTLA4-Ig)
in patients with podocyte B7-1–positive FSGS.12
CONCISE METHODS
Human Kidney Biopsies
Participants providedwritten informed consent and theOspedale San
Carlo (Milan, Italy) institutional review board approved this study.
Kidney biopsies obtained from individuals with T2D (n=30) at dif-
ferent stages of DN were collected. For every individual, a record of
medical history was available and serum and urine were collected to
obtain kidney functional data. Histologic samples obtained from the
unaffected kidney pole of individuals who underwent unilateral ne-
phrectomy for renal cancer (n=30) served as controls. Table 1 pro-
vides demographic and metabolic details of our cohort.
Genetic Studies in the Joslin Clinic Cohort
Study Population and Genotyping
A detailed description of the Joslin Study of Genetics of Nephropathy
in T2D collectionwas recently published.36We randomly selected 173
patients with DN with proteinuria, ESRD, or microalbuminuria and
CKD stage 4 or 5, along with 177 normoalbuminuric controls from
this collection, for whole genome genotyping on Illumina’s Human
CNV370v1 genotyping array (data available in dbGaP, http://www.
ncbi.nlm.nih.gov/gap/, accession number phs000302.v1.p1) (Illu-
mina, San Diego, CA). Previously described quality control measures
were applied to these data.37 The application of quality control met-
rics for minor allele frequency ,0.01, rejection of Hardy–Weinberg
assumptions (P#1025), and differential rates of missing data (by
case/control status) resulted in high-quality genotypic data for
324,382 autosomal SNPs. The application of quality control criteria
reduced the study population from 350 to 326 individuals of Euro-
pean ancestry. For case/control comparisons, strict phenotypic clas-
siﬁcation restricted our analysis to 142 patients with DN (113
proteinuric and 29 ESRD) and 151 normoalbuminuric controls.
ACR and eGFR data from all 326 individuals of European ancestry
were available for quantitative trait analysis. Genotypic data for all
SNPsmapping to the B7-1 and CD28 loci, including 10 kb of ﬂanking
sequence (NCBI Build 36.1 chromosome 3 position 120,715,830–
120,771,171 and chromosome 2 position 204,269,443–204,321,880,
respectively) were extracted from the genetic data. Within the 55.3 kb
B7-1 and 52.4 kb CD28 loci, data for 19 SNPs (12 and 7 SNPs, re-
spectively) were obtained. In addition, genotype data across the B7-1
locus were augmented by imputation of 57 ungenotyped SNPs across
this region usingMaCH (www.sph.umich.edu/csg/abecasis/MACH/)
software as previously described.37 In total, 69 SNPs (12 genotyped
and 57 imputed) with an average intermarker distance of 706 bp were
included in our association analysis at the B7-1 locus.
Statistical Analyses
Deviation from Hardy–Weinberg equilibrium was assessed for use
of a genotypic chi-squared test. Genotype data were analyzed using
additive tests of association to calculate P values and ORs. Quantita-
tive trait analyses were performed using available ACR measurement
data and cystatin-based eGFR. All statistical analyses were performed
using PLINK.38
Epidemiologic Studies in the Joslin Clinic Cohort
Cohort of Patients
Epidemiologic studies were performed on the Joslin Clinic cohort of
individuals with T2D followed for DN progression. For a more
detailed description of patient groups, please refer to Supplemental
Table 1. Only patients with increased urinary albumin excretion
(UAE) (in the microalbuminuria and proteinuria range) and avail-
able plasma samples at baseline were considered eligible for this
study. sB7-1 was measured by Instant ELISA (eBioscience, San Diego,
CA), whereas sCD28 and sCTLA4 were measured by Platinum ELISA
(eBioscience). Assay sensitivities were 0.18 ng/ml for sCD28, 0.10
ng/ml for sB7-1, and 0.13 ng/ml for sCTLA4. In our study, sCD28
was detectable in 90%, sB7-1 in 94%, and sCTLA4 in 4% of plasma
samples. ODs of sCD28 and sB7-1 were ﬁtted to a ﬁve-parameter
logistic standard curve with 1/y weighting usingMasterplex Readerﬁt
(v.1.1.4.52; Hitachi Software Engineering, Shinagawa, Japan).
Assessment of DN at Baseline
The results of urinalyses performedon these patients’urine during the
preceding 2-year interval were reviewed within the Joslin Clinic com-
puter database. The ACR value was converted to an albumin excre-
tion rate (AER) according to a previously published formula.39 For
Figure 8. Proposed model to explain the role of B7-1 and CTLA4-
Ig action in DN.
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each patient, the geometric mean AER for the preceding 2-year
interval was determined to assign albuminuria status as follows: micro-
albuminuria, AER 30–300 mg/min; and macroalbuminuria/protein-
uria, .300 mg/min.39,40 In 2009, plasma creatinine was measured in
stored baseline samples at the University of Minnesota with the Roche
enzymatic assay (Roche, Pleasanton, CA) on a Roche/Hitachi Mod P
analyzer. GFR was estimated from plasma concentrations of creatinine
using the IDMS-traceable Modiﬁcation of Diet in Renal Disease
(MDRD) formula.41 Individuals with evidence of nephropathy unre-
lated to diabetes and with CKD stages 4 and 542 were excluded.
Ascertainment of ESRD and Mortality
All individuals were queried against rosters of the US Renal Data
System (USRDS) and the National Death Index (NDI) covering all
events up to the end of 2004. The USRDSmaintains a roster of United
States patients receiving RRT and includes dates of dialysis and
transplantation.43,44 ESRD was deﬁned by a match with the USRDS
roster (n=39) or a listing of renal failure among the causes of death on
an NDI death certiﬁcate (n=16).
Statistical Analyses
Follow-up data were analyzed as incidence rates of ESRD or death
withoutESRDandwere tested for trend across quartiles of eachmarker
(B7-1 and CD28) distribution. The Cox proportional hazard model
was used to evaluate the independent effect of investigated markers.
The effect of quartiles of themarker distribution (categorical variable)
was examined in the univariate analysis and subsequently with an
adjustment by relevant clinical covariates. Statistical analysis was per-
formed with SAS software (version 9.2; SAS Institute, Inc., Cary, NC).
Statistical Analysis
Data are expressed as the mean6SEM. When two groups were com-
pared cross-sectionally, two-sided unpaired t tests (for parametric data)
or Mann–Whitney tests (for nonparametric data) were used according
to distribution. ANOVA (for parametric data) and Kruskal–Wallis tests
(for nonparametric data) were used. Post hoc analysis was chosen to
evaluate a posteriori pairwise comparisons, and the Bonferroni correc-
tionwas used to account formultiple comparisons. The chi-squared test
for categorical variables was used when necessary. A P value,0.05 (by
two-tailed testing)was considered an indicator of statistical signiﬁcance.
Data were analyzed using an SPSS statistical package for Windows
(SPSS, Inc., Chicago, IL). Prism software was used for drawing graphs
(GraphPad Software, Inc., San Diego, CA).
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